Byredo
Is Your Restraint a Choice or a Limitation?
In this issue
The Quarter in Brand Authority
The Brand Worth Watching — Byredo
The Vocabulary Shift
Category Signals
The Blind Spot
The Question
Prestige grew 2 percent in H1 2025. Mass grew 4 percent. The gap has narrowed to two percentage points, the smallest it has been since the post-pandemic prestige surge began. The narrowing is real but the composition matters: mass growth in H1 was fragrance-driven, and fragrance is normalizing from post-pandemic highs. Remove fragrance from the mass number and the two channels are essentially on par.
The Rhode acquisition at $1 billion is the most significant beauty transaction of the year. The category’s analysis has focused on the valuation, what e.l.f. paid for, whether the price was justified, what the DTC-to-retail transition implies for revenue sustainability. This Brief is tracking a different question: what happens to the brand’s authority with its consumer when the founder’s direct relationship with that consumer is intermediated by a conglomerate’s growth agenda?
Drunk Elephant is the prior data point. The answer it provided is on Shiseido’s balance sheet.
Ben Gorham’s departure from Byredo is confirmed as of June 2025. The contractual arrangement that this Brief has tracked since Q1 2024 has ended. The first post-Gorham fragrance collection is the diagnostic test the category needs.
The diagnostic question from Q1 2024 is now answerable in real time: can a brand whose authority was built from one founder’s interior life hold that authority when that interior life is no longer the source? The question is not whether Puig can produce good fragrance. They can. The question is whether fragrance produced without the specific biographical source that made Byredo’s authority non-replicable will carry the same signal for the consumer who chose Byredo because of that non-replicability.
The first post-Gorham collection will tell this Brief what it needs to know. The copy on the launch will tell the rest. If the language describes the fragrance in atmospheric terms that could belong to any niche fragrance house, the answer is visible before the first review is published.
Biotech is entering category vocabulary. Several brands are beginning to name fermentation technology, lab-grown actives, and biotechnology-derived ingredients specifically rather than describing them through outcomes alone. The term has more precision than clinical because it describes a production process rather than just claiming an outcome. The entering window is open. Brands with genuine biotech manufacturing have 12 to 18 months before the term reaches the mainstream saturation that began clinical’s commodification.
Skincare, fragrance, color cosmetics, hair, and wellness signals tracked across observation, validation, and forecast.
Skincare: Proof vocabulary mainstream. Longevity mainstream. Biotech entering. The vocabulary progression is consistent with the pattern this Brief has tracked since Q1 2024.
Fragrance: Normalization confirmed at 5 percent growth for H1, down from 14 percent full-year 2024. Structural growth. Not a decline. The category is finding its post-spike equilibrium.
Color Cosmetics: Skinification holding. The brands that built skin-benefit architecture are outperforming. The brands that added the language are softening.
Hair: Hair outperforming prestige total. Scalp care third consecutive year of double-digit growth. Professional authority premium holding.
Wellness: Longevity fully mainstream in wellness. Beginning to mainstream in prestige skincare. The window for specific ownership is narrowing.
The category has spent the past 18 months analyzing Drunk Elephant's decline through the lens of a brand that lost its core consumer to a younger one. That is accurate but incomplete.
Everyone is analyzing what e.l.f. paid for Rhode. Nobody is building a framework for what happens to brand authority when a founder-led acquisition moves past the handover. Byredo and Drunk Elephant are already running the experiment simultaneously. Rhode is about to become the third concurrent data point. The category will have more evidence on this question in the next 18 months than it has accumulated in the prior decade. The brands and investors paying attention to the pattern rather than the individual transactions will hold the most defensible analytical position in the category.
Is your restraint a choice or a limitation? The brands that hold back, that do not launch the line extension, do not expand into the adjacent category, do not take the retail door that would triple their distribution, sometimes do so because they understand what their authority rests on and they are protecting it. Sometimes they do so because they do not have the resources to execute the expansion credibly. The two things look identical from the outside. They produce very different outcomes. Which one is yours?